ITOCHU Announces Launch of AI Analysis Service for Medical and Health Data Analysis

First Partnership Agreement for DataRobot with a Domestic Contract Research Organization for Pharmaceutical Development

August 10, 2022

ITOCHU Corporation (headquartered in Minato-ku, Tokyo; Keita Ishii, President & COO; hereinafter "ITOCHU") announced today that it has signed a partnership agreement with a leading AI platform company DataRobot, Inc. (headquartered in Boston, Massachusetts; Dan Wright, CEO; hereinafter "DataRobot"), through ITOCHU's subsidiary A2 Healthcare Corporation (headquartered in Bunkyo-ku, Tokyo; Hitoshi Kamiya, President & Chief Executive Officer; hereinafter "A2 Healthcare"). This is the first agreement for DataRobot with a domestic contract research organization for pharmaceutical development*1 (hereinafter "CRO"). Through this agreement, ITOCHU will launch AI-based services for pharmaceutical and medical equipment companies such as medical and health data analysis.

The importance of using Real World Data (hereinafter "RWD") is growing in the pharmaceutical industry. Such data includes patient medical data based on medical treatment at clinical sites and health data regularly collected from various databases. The global market for usage conditions of pharmaceutical products and solutions generated by clinical evidence gained through RWD analysis is estimated to grow from around 1.2 billion USD in 2021 to about 2.3 billion USD by 2026.*2

DataRobot creates high-precision machine learning models in a short period of time and offers AI platforms to businesses to apply these models without the use of high-level technology. In addition to the automation of data preprocessing and predictive model development, these platforms feature monitoring functions from application to implementation, leading to successful use of AI in the healthcare industry not only in Japan but globally as well.
As a leading CRO in Japan, A2 Healthcare has more than 50 years of experience in the pharmaceutical industry. There are more than 50 data scientists in A2 Healthcare with knowledge of clinical development and has engaged in data analysis for pharmaceutical product and medical equipment companies. In April 2018, A2 Healthcare established a Real World Evidence Group, and have accumulated knowledge and experience related to RWD.

The AI analysis service offered by A2 Healthcare data scientists through the use of DataRobot's AI platform makes it possible to handle the sequential data taken from wearable devices as well as large amounts of data from gene analysis, allowing to construct more precise models that unlock the relationships between changes in disease condition and more. This will further strengthen previously known causal relationships between pharmaceutical products and their results, side effects, risk factors and clarify causal relationships that have not yet been solved. This service is hoped to discover effective prevention and treatment methods for diseases.

ITOCHU transforms business through its "market-in" approach, which is a basic policy included its medium-term management plan, and this effort is in line with this policy. ITOCHU and A2 Healthcare will continue to place the healthcare field as an area of focus and will continue to actively develop our business so that we may contribute to a society where better healthcare is provided through cooperation with businesses that create forward-thinking technologies and services.

Differences Between Conventional Data Analysis in the CRO Industry

  • *1CRO: an abbreviation for "Contract Research Organization" and an outsourced business engaged in work required in the development of pharmaceutical products (monitoring, data assessment, statistical analysis, etc.)
  • *2Source: Global Real World Evidence (RWE) Solutions Market with COVID-19 Impact Analysis (to 2026)
  • *DataRobot is a trademark of DataRobot, Inc.

A2 Healthcare Corporation

Location Bunkyo-ku, Tokyo
Representative Hitoshi Kamiya
Establishment July 2003
Business description Clinical development, post-marketing surveillance and clinical research services for development of pharmaceutical, medical devices, cellular and tissue-based products and vaccines

DataRobot, Inc.

Location Boston, MA
Representative Dan Wright
Establishment June 2012
Business description Offers a general purpose machine learning platform